| Endo Pharmaceuticals Holdings | (NQ: ENDP) |
|
USD
|
|
Official Closing Price
/ Updated: /
|
| View: | Quote | News | Research |
(ENDP) Community Analysis from
Bulls REASONS TO BUY
|
100%
agree
1 votes
|
Endo Pharmaceuticals: Steady Growth |
Bears REASONS TO SELL
May 25, 2013
(Stock Blog Hub,
3/6/13)
Actavis, Inc. (ACT) recently announced that it is looking to get its generic version of Endo Health Solutions Inc.’s (ENDP) Fortesta (testosterone gel 10mg/0.5g)...(read more)
(Stock Blog Hub,
6/20/12)
Endo Health Solutions (ENDP) recently announced that the transition of the company's Opana ER franchise to the new version, which is designed to be crush...(read more)
(Benzinga,
12/12/11)
One of the few things that pharmaceutical companies live for is to release life-changing drugs onto the public market. While pharmaceuticals do not expect to...(read more)
Endo Pharmaceuticals Holdings (ENDP) Company Overview
There is no analysis for ENDP yet. But you can go to Wikinvest to help create one!
What's in this ENDP analysis on Wikinvest...
- Company Overview
- Trends and Forces
- Market Conditions Have Constrained Endo's Access to Capital for Clinical Trials and Acquisitions
- Generic Competition Poses Threat to ENDO’s Highly Concentrated Drug Portfolio
- Regulators are Investigating Endo for "Off-Label" Prescription of Lidoderm
- Competition
- Oxycodone Brands
- Oxymorphone Brands
- References
